DiaMedica Therapeutics Inc.

We are thrilled to share a recent article published by Stellenbosch University titled “Researchers launch clinical trial testing a new promising preeclampsia drug.” This groundbreaking research features DiaMedica’s preeclampsia (PE) study and our investigational product, DM199. Read the full article on Stellenbosch University’s website here: https://lnkd.in/gyPzZJcQ You can also find more details about DiaMedica’s innovative work on preeclampsia and DM199 by visiting www.diamedica.com Thank you for your continued interest in DiaMedica and our commitment to improving the lives of people suffering from serious ischemic diseases!

We are excited to announce the formation of our Preeclampsia Scientific Advisory Board, a group of esteemed experts dedicated to advancing the development of DM199 for the treatment of preeclampsia. Meet the exceptional experts leading this groundbreaking initiative: 🔬 Professor Vincenzo Berghella Director of Maternal-Fetal Medicine at Thomas Jefferson University, with over 700 peer-reviewed publications in journals like The Lancet and AJOG-MFM. 🔬 Professor Cathy Cluver Founder of the Preeclampsia Research Unit at Stellenbosch University, South Africa, with extensive experience in preeclampsia treatment trials and biobanking. 🔬 Professor Bob Silver Chairman of Obstetrics & Gynecology at the University of Utah, focusing on stillbirth, placental complications, and preeclampsia, with over 400 peer-reviewed publications. 🔬 Professor Stephen Tong Globally recognized preeclampsia expert, driving translational research to develop innovative therapeutics, with works featured in Nature and The Lancet. 🔬 Professor Susan Walker Leader in maternal-fetal medicine at the University of Melbourne, with a focus on improving preeclampsia detection and treatment, and a recipient of Australia’s prestigious Order of Australia honor. We are thrilled to welcome these distinguished members to our Scientific Advisory Board! Read our full press release here: https://bit.ly/4fWexYb #Preeclampsia #HealthcareInnovation #DiaMedicaTherapeutics #ScientificLeadership $DMAC

We have just released our latest business update and third quarter 2024 financial results. 🔗Read our latest press release here: https://bit.ly/4fw6EZp Join us for a conference call and webcast to discuss these updates in detail: 📅 Date: Thursday, November 14, 2024  🕖 Time: 7:00 AM CT / 8:00 AM ET  🌐 Web access: https://lnkd.in/g_XtQCJ9  📞 Dial In: (646) 357-8785  🆔 Conference ID: 28056 Key Highlights: - Implemented Updates to AIS Program Intended to Enhance Probability of Trial Success and Expedite Study Completion, with Potential for a Reduced Study Size - Preeclampsia Phase 2 Trial Received Regulatory Approval and First Patient Dosed - Cash Runway Into Q3 2026 Stay tuned for more updates and join us for the call! #DiaMedica #BusinessUpdate #FinancialResults #ConferenceCall $DMAC

🌟 Exciting progress at DiaMedica Therapeutics! 🌟 We’re thrilled to announce that the first patient has been dosed in our investigator-sponsored Phase 2 trial of DM199 for preeclampsia (PE) treatment. This is a significant milestone for the entire medical community focused on improving maternal and fetal health. With top-line data for Part 1A expected in the first half of 2025, we’re hopeful for proof-of-concept results demonstrating DM199’s safety, blood pressure-lowering potential, and potential disease-modifying benefits for early onset PE. 📖 Read our full press release to learn more! https://bit.ly/3CAUf7O Dr. Lorianne Masuoka, DiaMedica Therapeutics’ Chief Medical Officer, shared, “This moment represents a crucial step forward in our mission to provide a safe and effective treatment for preeclampsia and is a testament to our team’s dedication and commitment. We are proud of this progress and remain focused on achieving our clinical goals.” #biotech #pharma #clinicaltrials #preeclampsia $DMAC

DiaMedica Therapeutics will be participating in the upcoming Craig-Hallum 15th Annual Alpha Select Conference in New York. Our management team will be on-site and available for one-on-one meetings throughout the day, providing a great opportunity for in-depth discussions. Join us as we share our latest advancements and future goals. 📄 Read our most recent press release to learn more: https://bit.ly/4fKYLzc #DiaMedica #HealthcareInnovation #CraigHallumAlphaSelect #PressRelease #InvestorConference $DMAC

📢 DiaMedica Q3 2024 Financial Results & Business Update 📢 We’re pleased to announce that DiaMedica will be providing a business update and reporting our Q3 2024 financial results. Join us for an in-depth look at our progress and plans for the future! 📅 Date: Thursday, November 14, 2024 🕖 Time: 7:00 AM CT / 8:00 AM ET 🌐 Web Access: https://lnkd.in/g_XtQCJ9 📞 Dial-In: (646) 357-8785 | Conference ID: 28056 Gain valuable insights into our journey and future direction! 🌟 Read our most recent press release here: https://bit.ly/3UDcdg4 #DiaMedica #FinancialResults #BusinessUpdate #ConferenceCall #InvestorRelations

🌎 Join us in raising awareness for World Stroke Day 🌎 At DiaMedica Therapeutics, we’re committed to developing innovative solutions to combat stroke's devastating effects. Our work with recombinant KLK1 (DM199) aims to improve the lives of people suffering from serious diseases with focus on acute ischemic stroke. 🔍 Did you know? Every 40 seconds, someone experiences a stroke. The faster treatment is received, the better the chances for recovery. This World Stroke Day, we encourage you to: ✅ Recognize the signs of stroke (F.A.S.T. – Face drooping, Arm weakness, Speech difficulty, Time to call 911) ✅ Spread awareness in your community ✅ Support advancements in stroke research and treatment Together, let’s make a difference in the fight against stroke! #WorldStrokeDay #StrokeAwareness #AcuteIschemicStroke #DiaMedicaTherapeutics #StrokeResearch #DM199 #GreaterThan

We're #hiring a new Head of Regulatory Affairs in Minnetonka, Minnesota. Apply today or share this post with your network.

We're thrilled to announce that DiaMedica Therapeutics has received regulatory approval to initiate our Phase 2 trial of DM199 in the treatment of preeclampsia. This is a critical step forward for a condition that impacts millions of pregnancies worldwide. First patient dosing is expected in Q4 2024, with proof-of-concept results targeted for the first half of 2025. Read the full press release here: https://bit.ly/47XFGqw Follow us on this important journey to improve maternal and fetal health outcomes! 🌟 #Preeclampsia #WomensHealth #ClinicalTrials #DiaMedica $DMAC

We're #hiring a new Accounts Payable Specialist in Minnetonka, Minnesota. Apply today or share this post with your network.